Andexxa Approval History
FDA Approved: Yes (First approved May 3, 2018)
Brand name: Andexxa
Generic name: coagulation factor Xa (recombinant), inactivated-zhzo
Company: Portola Pharmaceuticals, Inc.
Treatment for: Reversal of Anticoagulant Activity of Factor Xa Inhibitors
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Development History and FDA Approval Process for Andexxa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.